Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): A cohort study analysis

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Jansen, Klaus ^a,b   Haastert, Burkhard ^c   Michalik, Claudia ^a,d   Guignard, Adrienne ^e   Esser, Stefan ^a,f   Dupke, Stephan ^a,g   Plettenberg, Andreas ^a,h   Skaletz Rorowski, Adriane ^a,b   Brockmeyer, Norbert H ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c MediStatistica ^*  (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g Clinical Centre Driesener Straße   (Germany)

^h Ifi Institute   (Germany)

Author keywords

Herpes zoster; Highly active antiretroviral therapy; HIV; Risk factor analysis

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VIRUS TRANSMISSION; ADOLESCENT; AGED; ANALYSIS OF VARIANCE; CHILD; GERMANY; HIV INFECTIONS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GERMANY; HERPES ZOSTER; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84881121953     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-372     Document Type: Article

References (27)

1. Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982, 61(5):310-316.
2. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000, 342:635-645. 10.1056/NEJM200003023420906, 10699164.
3. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995, 155:1605-1609. 10.1001/archinte.1995.00430150071008, 7618983.
4. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20. 1898279, 14267505.
5. Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007, 11(Suppl 2):S43-S48.
6. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33. 10.1016/S1473-3099(03)00857-0, 14720565.
7. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, Holmberg SD. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992, 166:1153-1156. 10.1093/infdis/166.5.1153, 1308664.
8. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(2):370-375. 10.1093/clinids/21.2.370, 8562746.
9. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, Coutinho RA, van der Meer JT. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995, 9:1153-1158. 10.1097/00002030-199510000-00006, 8519451.
10. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633-642. 10.7326/0003-4819-124-7-199604010-00003, 8607591.
11. McNulty A, Li Y, Radtke U, Kaldor J, Rohrsheim R, Cooper DA, Donovan B. Herpes zoster and the prognosis of HIV-1 infection. Genitourin Med 1997, 73(6):467-470. 1195926, 9582462.
12. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005, 40:169-174. 10.1097/01.qai.0000178408.62675.b0, 16186734.
13. Vanhems P, Voisin L, Gayet-Ageron A, Trepo C, Cotte L, Peyramond D, Chidiac C, Touraine JL, Livrozet JM, Fabry J, Voirin N. The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005, 38:111-3.0. 10.1097/00126334-200501010-00020, 15608535.
14. Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH, Chang SC. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS 2005, 16:673-676. 10.1258/095646205774357271, 16212714.
15. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. J Am Med Assoc 2006, 296:292-300.
16. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. Primary varicella and Herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics 2008, 121(1):e150-e156. 10.1542/peds.2007-0564, 18086820.
17. Levin MJ, Anderson JP, Seage GR, Williams PL, PACTG/IMPAACT 219C Team Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr 2009, 50(2):182-191. 10.1097/QAI.0b013e31819550a4, 2748317, 19131890, PACTG/IMPAACT 219C Team.
18. Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, Maurer T, Young M, Dehovitz J, Ru J, Anastos K. Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004, 37:1604-1609. 10.1097/00126334-200412150-00013, 15577417.
19. Song JY, Lee JS, Jung HW, Choi HJ, Lee JS, Eom JS, Cheong HJ, Jung MH, Kim WJ. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study. J Acquir Immune Defic Syndr. 2010, 53:417-418. 10.1097/QAI.0b013e3181b1d6dc, 20190589.
20. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr 2012, 61(2):203-207. 10.1097/QAI.0b013e318266cd3c, 22766968.
21. Jansen K, Michalik C, Hahn M, Dupke S, Esser S, Jaeger H, Köppe S, Moll A, Plettenberg A, Schmidt RE, Skaletz-Rorowski A, Brockmeyer NH. Competence Network for HIV/AIDS: The patient cohort of the German Competence Network for HIV/AIDS (KompNet): A Profile. Eur J Med Res 2009, 14:323-331. 10.1186/2047-783X-14-8-323, 3352164, 19666392.
22. Jansen K, Brockmeyer NH, Hahn M, Kaul I, Fenske S, Rausch M, Kuhlmann B, Ulmer A, Lauenroth-Mai E, Harrer T, Hower M, Skaletz-Rorowski A, Michalik C. Competence Network for HIV/AIDS: Epidemiological composition, clinical and treatment characteristics of the patient cohort of the German Competence Network for HIV/AIDS. Eur J Med Res 2009, 14:415-425. 3352224, 19748848.
23. Kleinbaum DG, Klein M. Survival analysis: A self-learning text 2005, New York: Springer, 2.
24. Robert Koch-Institut Zum Welt AIDS-Tag 2010. Epidemiologisches Bulleti 2010, 46:454-459. Robert Koch-Institut.
25. Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007, 104:455-460. 10.1016/j.tripleo.2007.02.001, 17604657.
26. Melbye M, Grossman RJ, Goedert JJ, Eyster ME, Biggar RJ. Risk of AIDS after herpes zoster. Lancet 1987, 1:728-731.
27. Alliegro MB, Dorrucci M, Pezzotti P, Rezza G, Sinicco A, Barbanera M, Castelli F, Tarantini G, Petrucci A. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study. Clin Infect Dis 1996, 23:990-995. 10.1093/clinids/23.5.990, 8922791.